ABEO: -55% | Abeona Therapeutics shares are trading lower after the company announced the FDA issued a Complete Response Letter in response to the company's Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.
CDNS: -10% | Cadence Design System shares are trading lower after the company issued Q2 adjusted EPS and sales guidance below estimates.
IBRX: 41% | ImmunityBio Has Received FDA Approval For ANKTIVA, A First-In-Class IL-15 Receptor Agonist, For BCG-Unresponsive Non-Muscle Invasive Bladder Cancer